0 310

Cited 43 times in

Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy

DC FieldValueLanguage
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author송기준-
dc.contributor.author안상훈-
dc.contributor.author한광협-
dc.date.accessioned2018-03-26T17:06:48Z-
dc.date.available2018-03-26T17:06:48Z-
dc.date.issued2015-
dc.identifier.issn0270-9139-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/157205-
dc.description.abstractSeveral risk prediction models have been created to predict hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) occurrence, with promising results. However, their prognostic performances need to be validated in the era of antiviral therapy. From 2006 to 2011, patients with chronic HBV infection were recruited and those with a history of HCC or hepatic decompensation were excluded. At enrollment, liver stiffness (LS) was measured using transient elastography. We assessed the performances of conventional HCC prediction models (CU-HCC, GAG-HCC, REACH-B, and LSM-HCC scores) and the modified REACH-B (mREACH-B) score where LS values were incorporated into REACH-B score instead of serum HBV-DNA levels. Of 1,308 subjects analyzed, the median age was 50.0 years (883 men). During the follow-up (median, 75.3 months), HCC developed in 125 (9.6%) patients. mREACH-B score had the highest areas under the receiver operating characteristic curves (AUROCs) for the prediction of HCC development at 3/5 years (0.828/0.806), compared with LSM-HCC (0.777/0.759), GAG-HCC (0.751/0.757), REACH-B (0.717/0.699), and CU-HCC (0.698/0.700) scores, respectively, with statistical significances (all P values <0.05 vs. mREACH-B). When serum HBV-DNA levels were excluded from the formula for REACH-B score, AUROCs for HCC development at 3/5 years improved paradoxically (from 0.717/0.699 to 0.757/0.732, respectively). In patients with antiviral therapy (n = 848), mREACH-B score had the better prognostic performances for HCC development at 3/5 years, compared to other prediction models. However, in patients without antiviral therapy (n = 460), it had the prognostic performances comparable to those of other prediction models. CONCLUSIONS: Prognostic performances of mREACH-B score seemed better compared to conventional models. In the era of antiviral therapy, incorporation of serum HBV-DNA level should be applied cautiously and individual risks should be assessed effectively based on the fibrotic burden.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherWiley-
dc.relation.isPartOfHEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAntiviral Agents/therapeutic use-
dc.subject.MESHCarcinoma, Hepatocellular/epidemiology-
dc.subject.MESHCarcinoma, Hepatocellular/virology*-
dc.subject.MESHFemale-
dc.subject.MESHHepatitis B/complications*-
dc.subject.MESHHepatitis B/drug therapy-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms/epidemiology-
dc.subject.MESHLiver Neoplasms/virology*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHModels, Statistical*-
dc.subject.MESHRisk Assessment-
dc.titleValidation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorKyu Sik Jung-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorKijun Song-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorKwang-Hyub Han-
dc.identifier.doi10.1002/hep.28115-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02016-
dc.contributor.localIdA02226-
dc.contributor.localIdA04268-
dc.relation.journalcodeJ00985-
dc.identifier.eissn1527-3350-
dc.identifier.pmid26249025-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1002/hep.28115/abstract-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameSong, Ki Jun-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorSong, Ki Jun-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.citation.volume62-
dc.citation.number6-
dc.citation.startPage1757-
dc.citation.endPage1766-
dc.identifier.bibliographicCitationHEPATOLOGY, Vol.62(6) : 1757-1766, 2015-
dc.identifier.rimsid41765-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.